ATE502650T1 - Verfahren zur befestigung von effektor-molekülen an proteinen - Google Patents

Verfahren zur befestigung von effektor-molekülen an proteinen

Info

Publication number
ATE502650T1
ATE502650T1 AT06744294T AT06744294T ATE502650T1 AT E502650 T1 ATE502650 T1 AT E502650T1 AT 06744294 T AT06744294 T AT 06744294T AT 06744294 T AT06744294 T AT 06744294T AT E502650 T1 ATE502650 T1 AT E502650T1
Authority
AT
Austria
Prior art keywords
protein
effector molecules
proteins
attaching
cysteines
Prior art date
Application number
AT06744294T
Other languages
English (en)
Inventor
Sam Philip Heywood
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE502650T1 publication Critical patent/ATE502650T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Catalysts (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Jellies, Jams, And Syrups (AREA)
AT06744294T 2005-07-06 2006-06-29 Verfahren zur befestigung von effektor-molekülen an proteinen ATE502650T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0513852.4A GB0513852D0 (en) 2005-07-06 2005-07-06 Biological products
PCT/GB2006/002416 WO2007003898A1 (en) 2005-07-06 2006-06-29 Process for attaching effector molecules to proteins

Publications (1)

Publication Number Publication Date
ATE502650T1 true ATE502650T1 (de) 2011-04-15

Family

ID=34856761

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06744294T ATE502650T1 (de) 2005-07-06 2006-06-29 Verfahren zur befestigung von effektor-molekülen an proteinen

Country Status (15)

Country Link
US (1) US8378073B2 (de)
EP (1) EP1912673B1 (de)
JP (1) JP5203188B2 (de)
CN (1) CN101212984B (de)
AT (1) ATE502650T1 (de)
AU (1) AU2006264684B2 (de)
CA (1) CA2613481C (de)
DE (1) DE602006020878D1 (de)
DK (1) DK1912673T3 (de)
ES (1) ES2361096T3 (de)
GB (1) GB0513852D0 (de)
PL (1) PL1912673T3 (de)
PT (1) PT1912673E (de)
SI (1) SI1912673T1 (de)
WO (1) WO2007003898A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100107501A (ko) * 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
AU2010216152B2 (en) 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
WO2013004844A1 (en) 2011-07-07 2013-01-10 Novo Nordisk A/S Drug delivery injection pen with add-on dose capturing and display module
EP3539982B1 (de) 2011-12-23 2025-02-19 Pfizer Inc. Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
EP3079722B1 (de) * 2013-12-13 2021-03-24 Novo Nordisk Health Care AG Verfahren zur thioetherkonjugation von proteinen
MX2016010295A (es) * 2014-02-11 2016-10-17 Seattle Genetics Inc Reduccion selectiva de proteinas.
GB201419184D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
ES3046837T3 (en) 2014-12-22 2025-12-02 UCB Biopharma SRL Method of protein manufacture
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016196017A1 (en) 2015-06-04 2016-12-08 Antriabio, Inc. Amine pegylation methods for the preparation of site-specific protein conjugates
EP3824906A1 (de) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antikörperformulierungen
MX2019009372A (es) * 2017-02-08 2019-12-11 Pfizer Produccion a gran escala para cisteinas de anticuerpo protegidas y no protegidas y su uso en la conjugacion de proteinas terapeuticas.
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
WO2019183671A1 (en) * 2018-03-28 2019-10-03 Proteomics International Pty Ltd Methods for measuring relative oxidation levels of a protein
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
US20240067758A1 (en) 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
BR112023008265A2 (pt) 2020-12-07 2024-02-06 UCB Biopharma SRL Anticorpos contra interleucina-22
AR125732A1 (es) 2021-05-03 2023-08-09 UCB Biopharma SRL Anticuerpos anti-trem1
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728430A (en) * 1986-02-10 1988-03-01 Millipore Corporation Diafiltration method
US5216183A (en) * 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
US5225194A (en) * 1989-11-13 1993-07-06 Ldc Research Corporation Aqueous diafiltration process for preparing acellular vaccines, against selected bacterial diseases
AU1140495A (en) * 1994-01-27 1995-08-03 Bristol-Myers Squibb Company Method for preparing thioether conjugates
US20040121415A1 (en) * 1996-12-10 2004-06-24 King David John Monovalent antibody fragments
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6423231B1 (en) * 1998-10-30 2002-07-23 Nephros, Inc. Non-isosmotic diafiltration system
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6406631B1 (en) * 1999-07-30 2002-06-18 Nephros, Inc. Two stage diafiltration method and apparatus
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
CN1621091A (zh) * 2003-11-28 2005-06-01 付经国 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US7908694B1 (en) * 2008-09-24 2011-03-22 Robert Sloane Mattress cover apparatus with integrated seals

Also Published As

Publication number Publication date
AU2006264684B2 (en) 2011-11-03
GB0513852D0 (en) 2005-08-10
US8378073B2 (en) 2013-02-19
EP1912673A1 (de) 2008-04-23
CN101212984A (zh) 2008-07-02
EP1912673B1 (de) 2011-03-23
DE602006020878D1 (de) 2011-05-05
PL1912673T3 (pl) 2011-07-29
WO2007003898A8 (en) 2008-10-09
JP2008544976A (ja) 2008-12-11
ES2361096T3 (es) 2011-06-13
SI1912673T1 (sl) 2011-10-28
WO2007003898A1 (en) 2007-01-11
CA2613481C (en) 2014-11-25
JP5203188B2 (ja) 2013-06-05
PT1912673E (pt) 2011-04-14
CA2613481A1 (en) 2007-01-11
DK1912673T3 (da) 2011-05-02
AU2006264684A1 (en) 2007-01-11
US20080306246A1 (en) 2008-12-11
CN101212984B (zh) 2011-09-28

Similar Documents

Publication Publication Date Title
DE602006020878D1 (de) Verfahren zur befestigung von effektor-molekülen an proteinen
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
WO2009052396A3 (en) Novel process for solubilizing protein from a proteinaceous material and compositions thereof
DE602006014846D1 (de) Verfahren zur quantifizierung von allergenen
ATE513872T1 (de) Verfahren zur herstellung von kautschukmischungen
DE602007007666D1 (de) Verfahren zur herstellung von nebivolol
DE602004013783D1 (de) Verfahren zur herstellung von thiocarboxylatsilan
EP4117458A4 (de) Verfahren zur herstellung von gersteprotein
EA201491155A1 (ru) Новые мутантные про-нрф и их применение для получения бета-нрф
DE602006017918D1 (de) Verfahren zur Herstellung von Telmisartan
ATE506370T1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors
DE502006006803D1 (de) Verfahren zur herstellung von leder
DE60322852D1 (de) Verfahren zur herstellung von eplerenon
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
DE602006019870D1 (de) Verfahren zur synthese von triazolen
ATE461934T1 (de) Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-car onsäure -lacton und schlüsselzwischenprodukte für dieses verfahren
EA200701852A1 (ru) Производные аминокислот
DE602006021124D1 (de) Verfahren zur Herstellung von Gummibestandteilen für Luftreifen
DE602006003769D1 (de) Verfahren zur herstellung von 4-amino-4'-demethyl-4-desoxypodophylotoxin
BRPI0608020A2 (pt) processo para a produção de uma composição contendo proteìna de soja e composição contendo proteìna de soja
DE602004002692D1 (de) Verfahren zur Herstellung von Topiramate
TW200706951A (en) Emireflective display and method thereof
ATE400574T1 (de) Pyrrolopyridin-2-karbonsäureamid-derivat zur verwendung als inhibitor gegen glykogenphosphorylase
ATE528312T1 (de) Verfahren zur synthese von makroliden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1912673

Country of ref document: EP